17-Beta-Estradiol Eluting Stent Versus Phosphorylcholine-Coated Stent for the Treatment of Native Coronary Artery Disease - 21/08/11
Doi : 10.1016/j.amjcard.2005.04.040
Flavio Airoldi, MD b, Carlo Di Mario, MD, PhD a, b, Flavio Ribichini, MD c, Patrizia Presbitero, MD d, Paolo Sganzerla, MD e, Valeria Ferrero, MD c, Corrado Vassanelli, MD c, Carlo Briguori, MD, PhD b, Mauro Carlino, MD b, Matteo Montorfano, MD b, Giuseppe G.L. Biondi-Zoccai, MD b, Alaide Chieffo, MD b, Angela Ferrari, PhD b, Antonio Colombo, MD a, b, ⁎ 
a EMO Centro Cuore, Columbus Clinic, Milan, Italy
b Interventional Cardiology Unit, San Raffaele Hospital, Milan, Italy
c Interventional Cardiology Unit, University of Piemonte Orientale, Novara, Italy
d Interventional Cardiology Unit, Istituto Clinico Humanitas, Rozzano, Milan, Italy
e Department of Cardiology, Cliniche Gavazzeni, Bergamo, Italy
Corresponding author: Tel.: 39-02-481-2920; fax: 39-02-481-9343.Résumé |
In this study we randomly compared the estradiol eluting stent (17-β-E) with phosphorylcholine (PC)-coated stents in native coronary arteries. The incidence of angiographic restenosis was 23% in the 17-β-E group and 31% in the PC group (p = 0.34). The major adverse cardiovascular event rates were also similar in the 2 groups (17% in the 17-β-E group vs 22% in the PC group, p = 0.47). The mid-term clinical and angiographic outcomes did not indicate superiority of the 17-β-E eluting stent over the control PC stent.
Le texte complet de cet article est disponible en PDF.© 2005
Elsevier Inc. Tous droits réservés.
Vol 96 - N° 5
P. 664-667 - septembre 2005 Retour au numéro
Article précédent
- Effectiveness of the Concomitant Use of Bivalirudin and Drug-Eluting Stents (from the Prospective, Multicenter BivAlirudin and Drug-Eluting STents [ADEST] Study)
- George Dangas, Zoran Lasic, Roxana Mehran, David Cox, Magdi G.H. Ghali, Timothy D. Henry, Paul S. Teirstein, Joseph F. Stella, Kevin F. Browne, Stephen Alan Lewis, William Knopf, Martin B. Leon, Jeffrey W. Moses, Gregg W. Stone
- Impact and Temporal Trends of Percutaneous Coronary Intervention in the Drug-Eluting Stent Versus Bare Metal Stent Eras
- Craig A. Thompson, Aaron V. Kaplan, John E. Jayne, Bruce J. Friedman, Bruce D. Hettleman, Nathaniel W. Niles, John F. Robb
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?